BBLG | Bone Biologics Corporation Annual & Quarterly

Annual Income Statements

(In USD)

Breakdown	2023	2022	2021	2020	2019	2018
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	50.00	96.00
Gross Profit	-	-	-	-	-50.00	-96.00
Operating Expenses	9.42 Million	3.66 Million	1.1 Million	825.01 Thousand	2.44 Million	2.79 Million
Selling, General and Administrative Expenses	2.52 Million	2.08 Million	1.01 Million	484.34 Thousand	1.35 Million	2.68 Million
Research and Development Expenses	6.9 Million	1.57 Million	82.04 Thousand	340.67 Thousand	1.09 Million	104.49 Thousand
Other Expenses	-	-	-	-	-	104.49 Thousand
Cost and Expenses	9.42 Million	3.66 Million	1.1 Million	825.01 Thousand	2.44 Million	2.79 Million
Operating Income	-9.42 Million	-3.66 Million	-1.1 Million	-825.01 Thousand	-2.44 Million	-2.79 Million
Interest Expense	-	-	805.1 Thousand	998.07 Thousand	975.77 Thousand	1.22 Million
Income Tax Expense	-	-2.18 Million	1600.00	1600.00	1603.00	1729.00
Earnings before Tax	-8.94 Million	-1.48 Million	-1.6 Million	-1.82 Million	-3.42 Million	-4.42 Million
Net Income	-8.94 Million	695.93 Thousand	-1.61 Million	-1.82 Million	-3.42 Million	-4.43 Million
Earnings Per Share Basic	-34.01	-31.15	-37.35	-35.68	-66.97	-
Earnings Per Share Diluted	-34.01	-31.15	-37.35	-35.68	-66.97	-
Weighted Average Shares Outstanding	263.13 Thousand	47 Thousand	43 Thousand	51 Thousand	51 Thousand	-
Weighted Average Shares Outstanding (Diluted)	263.13 Thousand	47.65 Thousand	43.12 Thousand	51.13 Thousand	51.13 Thousand	-
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	479.57 Thousand	-	-	-825.01 Thousand	-2.44 Million	-2.79 Million
Earnings Before Tax Margin	-	-	-	-	-	-

Breakdown	2024 Q2	2024 Q1	2023 Q4	2023 FY	2023 Q3	2023 Q2
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	809.66 Thousand	903.53 Thousand	1.16 Million	9.42 Million	2.08 Million	3.03 Million
Selling, General and Administrative Expenses	459.22 Thousand	657.91 Thousand	712.93 Thousand	-	506.04 Thousand	744.61 Thousand
Research and Development Expenses	350.44 Thousand	245.62 Thousand	447.07 Thousand	-	1.57 Million	2.29 Million
Other Expenses	-	-	-	-	-	-
Cost and Expenses	809.66 Thousand	903.53 Thousand	1.16 Million	9.42 Million	2.08 Million	3.03 Million
Operating Income	-809.66 Thousand	-903.54 Thousand	-1.16 Million	-9.42 Million	-2.08 Million	-3.03 Million
Interest Expense	-	-	-562.36 Thousand	-	-	-
Income Tax Expense	-809.66 Thousand	-903.53 Thousand	-349.00	-9428.30	-2080.89	-428.00
Earnings before Tax	-783.73 Thousand	-865.97 Thousand	-1.54 Million	-8.94 Million	-1.91 Million	-1.76 Million
Net Income	-783.73 Thousand	-865.97 Thousand	-1.54 Million	-8.94 Million	-1.91 Million	-1.76 Million
Earnings Per Share Basic	-0.67	-1.31	-2.90	-	-4.90	-13.52
Earnings Per Share Diluted	-0.67	-1.31	-2.90	-	-4.90	-13.52
Weighted Average Shares Outstanding	1.16 Million	660.92 Thousand	534.23 Thousand	263.13 Thousand	391.79 Thousand	130.87 Thousand
Weighted Average Shares Outstanding (Diluted)	1.16 Million	660.92 Thousand	534.23 Thousand	263.13 Thousand	391.79 Thousand	130.87 Thousand
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-809.66 Thousand	-903.54 Thousand	-769.78 Thousand	-	-2.08 Million	-4.31 Million
Earnings Before Tax Margin	-	-	-	-	-	-